Geoffrey I Shapiro
Dana-Farber - Harvard Cancer Center LAO · Alliance for Clinical Trials in Oncology · Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Geoffrey I Shapiro as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:04 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05687110 · Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair GenesNational Cancer Institute (NCI) · recruiting · Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm · principal investigator
- Ph2NCT05554367 · Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment TrialNational Cancer Institute (NCI) · active not recruiting · Exocrine Pancreas Carcinoma, Malignant Solid Neoplasm, Ovarian Low Grade Serous Adenocarcinoma · principal investigator
- Ph1/Ph2NCT04116359 · Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT CarcinomaNational Cancer Institute (NCI) · withdrawn · Metastatic NUT Carcinoma, Unresectable NUT Carcinoma · principal investigator
- Ph1NCT03113188 · CBP501, Cisplatin and Nivolumab in Advanced Refractory TumorsCanBas Co. Ltd. · completed · Advanced Solid Tumors · principal investigator
- Ph1NCT01434316 · Veliparib and Dinaciclib in Treating Patients With Advanced Solid TumorsNational Cancer Institute (NCI) · active not recruiting · Advanced Malignant Solid Neoplasm · principal investigator
- Ph1NCT00075933 · ARQ 501 in Subjects With CancerArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · completed · Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:04 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Dana Farber/Harvard Cancer Center Specialized Program of Research Excellence in Breast CancerP50CA168504 · NCI · DANA-FARBER CANCER INST · fiscal years 2021 to 2026 · $2,525,262 awarded in 2026Same name and institution; not confirmed by an ID
- Extension of the Dana Farber Harvard Cancer Center Consortium for the ETCTNUM1CA186709 · NCI · DANA-FARBER CANCER INST · fiscal years 2014 to 2026 · $2,272,446 awarded in 2026Grant number is on one of their registry trials
- Pathology CoreP01CA269021 · NCI · DANA-FARBER CANCER INST · fiscal years 2024 to 2026 · $411,436 awarded in 2026Same name and institution; not confirmed by an ID
- Program 12: Developmental TherapeuticsP30CA006516 · NCI · DANA-FARBER CANCER INST · fiscal years 2020 to 2026 · $48,206 awarded in 2026Grant number is on one of their registry trials
- Novobiocin-mediated polymerase theta inhibition in homologous recombination repair-deficient cancersR01CA272982 · NCI · DANA-FARBER CANCER INST · fiscal years 2022 to 2025 · $795,857 awarded in 2025Same name and institution; not confirmed by an ID
- ATR inhibitor-mediated reversal of PARP inhibitor resistance in high-grade serous ovarian cancer (HGSOS)P50CA240243 · NCI · DANA-FARBER CANCER INST · fiscal years 2020 to 2024 · $393,712 awarded in 2024Same name and institution; not confirmed by an ID
- Cyclin-Dependent Kinase Inhibition During S PhaseR01CA090687 · NCI · DANA-FARBER CANCER INST · fiscal years 2001 to 2014 · $296,988 awarded in 2014Grant number is on one of their registry trials
- Translational studies of Hsp90 inhibitors in NSCLCP50CA090578 · NCI · DANA-FARBER CANCER INST · fiscal years 2008 to 2009 · $195,254 awarded in 2009Same name and institution; not confirmed by an ID
- IDENTIFICATION OF CYCLIN C ASSOCIATED PROTEINSK08CA073700 · NCI · DANA-FARBER CANCER INST · fiscal years 1997 to 1998 · $77,061 awarded in 1998Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Alliance for Clinical Trials in Oncology Member Site CoreU10CA180821 · NCI · ALLIANCE NCTN FOUNDATION · PI Evanthia Galanis · fiscal years 2014 to 2026Named on NCT05554367
- Early Clinical Trials of New Anti-Cancer Agents with Phase I EmphasisU01CA062490 · NCI · DANA-FARBER CANCER INST · PI DONALD W. KUFE · fiscal years 1994 to 2013Named on NCT01434316
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:04 UTC. The ranking covers the 200 most relevant of 142 PubMed records, and a shared surname and initials can bring in a namesake. All 142 on PubMed
- Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.N Engl J Med · 20103,653 citationsRCR 86.4
- Crizotinib in ROS1-rearranged non-small-cell lung cancer.N Engl J Med · 20141,567 citationsRCR 42.3
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.N Engl J Med · 20201,444 citationsRCR 58.9
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.Lancet Oncol · 20121,021 citationsRCR 26.5
- Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.N Engl J Med · 2010685 citationsRCR 16.4
- 650 citationsRCR 20.3
- First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.Cancer Discov · 2013556 citationsRCR 16.1
- Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.J Clin Oncol · 2011512 citationsRCR 11.8
- Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.Clin Cancer Res · 2012468 citationsRCR 11.4
- Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.N Engl J Med · 2015464 citationsRCR 12.7